地诺单抗在哪可以买到？

(denosumab, also known as AMG-162, trade name Prolia) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA. In addition, denosumab is a drug that targets the RANK ligand. Compared with the bisphosphonates that have been used clinically, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously and is easy to use. Clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates does. The dosing speed is determined based on the patient's renal function monitoring; however, denosumab is currently relatively expensive, and the balance between its long-term efficacy and cost-effectiveness needs to be further confirmed. It is expected that denosumab, a drug specifically targeting RANK ligand inhibitors, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.

In 2011, in a randomized, double-blind trial of denosumab versus zoledronic acid, Henry et al. reported that denosumab was no less effective than zoledronic acid in reducing or preventing skeletal-related events (SREs) in patients with advanced cancer (breast cancer, prostate cancer) bone metastasis and multiple myeloma. Based on the above and related clinical research findings, the FDA (U.S. Food and Drug Administration) in 2010 and the EMA (European Medicines Agency) in 2011 approved denosumab for osteoporosis (postmenopausal osteoporosis), delaying the occurrence of bone-related events in patients with bone metastases, and bone loss induced by aromatase and androgen deficiency.

Denosumab is not available in China because it was conditionally approved and only approved for a few months. Therefore, denosumab has not been popularized yet and is not accessible to ordinary patients. The price of the original drug in the United States is high and most patients cannot afford it. The price of the original drug in Turkey is the lowest in the world. Patients can go to Turkey to buy it in person or obtain it through domestic professional overseas medical service institutions.